December 2017 Transpharmation Ireland Ltd. is proud to have organised the annual Irish Neuroscience Social.
The annual Irish Neuroscience Social, hosted by Irish Ambassador Dan Mulhall in Washington, DC in conjunction with Neuroscience Ireland, is organised as a satellite social event to the Society for Neuroscience (SFN) meeting which took place 11-15th November.
The Irish Neuroscience Social 2017 was organised by Transpharmation Ireland Ltd. in conjunction with Neuroscience Ireland. Following the inspiring speech of Ambassador Dan Mulhall, Professor John Cryan (University College Cork) and Dr. Max Bianchi (Transpharmation Ireland Ltd.) gave two short speeches to update on the progress of Neuroscience Research in Ireland from academia and industry, respectively.
Dr Jack Prenderville (Transpharmation Ireland. Ltd.) delivered a welcome speech on behalf of Neuroscience Ireland and acknowledged all the organisers of the event.
In the picture from left to right, Dr Max Bianchi (General Manager and Scientific Director at Transpharmation Ireland Ltd.), Ambassador Dan Mulhall, Dr Jack Prenderville (Principal Scientist at Transpharmation Ireland Ltd.) and Conor McDonnell (Scientist at Transpharmation Ireland Ltd.).
November 2017 InterVivo Solutions and Transpharmation enter into Co-Marketing and Co-Development Joint Venture.
TORONTO, Canada and LONDON, UK – November 12, 2017 – InterVivo Solutions Inc., a Canadian-based contract research organization, and Transpharmation Ltd., a UK/European-based contract research organization, announced today a strategic joint venture to co-market and co-develop an expansive suite of translational research services that will assist global pharmaceutical and biotech industries develop novel therapeutics to treat diseases of the Central Nervous System (CNS). Both companies have a pre-existing Global client base built on a scientific reputation of ‘best in class’ translational Drug Discovery support.
Mark Duxon, CEO of Transpharmation said, “We are excited to enter into this co-marketing agreement with InterVivo Solutions. The joint venture will provide our clients with seamless access to complimentary services that place our companies as leaders in the CNS therapeutic development space”.
Joseph Araujo, CEO of InterVivo added, “The bridging of Transpharmation’s expertise in EEG, biomarkers and human experimental medicine capabilities with InterVivo’s translation approach and aged models of disease augments both our companies translational strategies that ultimately will improve our clients ability to develop drugs that will bring clinically relevant benefits to patients and their families”.
About InterVivo Solutions
InterVivo is a Canadian-based preclinical contract research organization with a mission to develop and provide translational animal models and transformative research services in an effort to improve the clinical success of new therapeutics, particularly in Central Nervous System indications. In addition to drug metabolism, exploratory safety and pharmacokinetics screening, InterVivo provides rodent models of cognitive dysfunction, obesity, abuse liability, pain and epilepsy, and Parkinson’s disease. InterVivo also provides a natural aging canine model of human diseases with a particular emphasis on Alzheimer’s disease progression, osteoarthritis, obesity, cancer and metabolic disorders.
Spun out of GlaxoSmithKline Pharmaceuticals (GSK) in 2010, Transpharmation has rapidly established itself as a leading provider of translational pharmacology services to the Pharmaceutical and Biotech industry. With a leadership team taken from GSK Neuroscience, Transpharmation now has a Global reach, helping clients across the USA, European Union and Asia. Building on its expertise in Behavioral Pharmacology and EEG, Transpharmation opened an Irish Subsidiary, Transpharmation Ireland, that has quickly established itself as a premier provider of biomarker analysis in preclinical and clinical studies.
October 2017 Transpharmation Ltd. will be attending the BioJapan conference.
This year, in Yokohama, Transpharmation Ltd. will be attending the BioJapan Conference. We look forward to welcoming you to booth C-72, where our team will be based.
September 2017 Transpharmation Ireland Ltd. sponsored the Brain for Business workshop.
Transpharmation Ireland Ltd. proudly sponsored the Brain for Business workshop.
August 2017 Transpharmation Ireland Ltd. at the CINP, the BAP meeting and Neuroscience Ireland.
Transpharmation Ireland Ltd. presented our latest research on Treatment resistant Depression at the CINP World Congress of Neuropsychopharmacology in Prague and the BAP Summer meeting held at Harrogate (UK) and Neuroscience Ireland (Galway).
See below some pictures of the team who were involved in presenting this research.
Dr. Jack Prenderville (Principal Scientist):
Conor McDonnell (Scientist):
Fionn Dunphy-Doherty (research assistant):
Teresa Burke (Junior Scientist):
and Amy Fisher (Undergraduate Student):
Not included in the pictures, but also involved was Dr. Ewa Sokolowska (Senior Scientist).
June 2017 Transpharmation Ireland Ltd. at the WFSBP 2017 in Copenhagen.
Dr. Massimiliano Bianchi and Dr. Jack Prenderville, from Transpharmation Ireland Ltd., attended the WFSBP in Copenhagen.
See below a picture Dr. Jack Prenderville talking at the conference –
See also a picture of Dr. Max Bianchi –
February 2017 Transpharmation Ireland’s, Dr. Max Bianchi, addresses the 5th Annual World CNS Summit.
On our recent attendance to the 5th CNS Summit in Boston, the General Manager and Scientific Director of Transpharmation Ireland, Dr. Max Bianchi, gave a first viewing to Pharma and Academia of our human/cross species biomarkers.
See below a picture of Max talking at the conference –
February 2017 Transpharmation to sponsor the 5th Annual World CNS Summit.
Transpharmation is pleased to announce that it will be sponsoring and attending the 5th Annual World CNS Summit, to be held in Boston, USA, 20-22nd February, 2017.
In addition to the attendance of our CEO and CSO, our Head of Transpharmation Ireland, Dr Max Bianchi, will also be talking about recent work in the development of preclinical and clinical biomarkers of Neurodegeneration and Tauopathies.
We look forward to meeting you in Boston and discussing some great science!
December 2016 Transpharmation expands its Psychiatry and Neurology molecular biomarker platform.
Transpharmation is pleased to announce the release of a new video, highlighting our commitment to providing Translational Biomarkers. We have recently added tissue, plasma and CSF from patients with Major Depressive Disorder (MDD), Schizophrenia, Alzheimer’s Disease and Mild Cognitive Impairment (MCI).
To watch the video, please click below –
November 2016 The Neurobiology of Depression. How to beat the disease of the 21st Century?
Transpharmation Ireland’s Dr. Max Bianchi (General Manager and Scientific Director) spoke at the IIC (Institute of Italian Culture) in Dublin about the Neurobiology of Depression.
These were just some of the questions tackled by Dr. Max Bianchi, who presented the discoveries of his team with the aim of facilitating the understanding of depression by the public.
For more information on our work with Treatment Resistant Depression, please contact us on – email@example.com
See below Dr. Max Bianchi talking at the IIC –
November 2016 Transpharmation to exhibit at the Society for Neuroscience.
Once again, we are pleased to announce that we will be exhibiting at the Society for Neuroscience (SFN) meeting in San Diego next week (Booth#329).
Please come and see us for a chat in San Diego or contact us on – firstname.lastname@example.org
September 2016 Transpharmation Ireland Ltd. attend Neuroscience Ireland 2016 Young Neuroscientists Symposium.
This year, on September 1st, the Neuroscience Ireland Symposium, aimed at promoting the research of early career investigators, was held at Trinity College Dublin. The Symposium was sponsored by Transpharmation Ireland Ltd. and the organising committee included Transpharmation staff Dr Jack Prenderville (Chair) and Dr Jennifer Rouine (Treasurer).
See below a picture of our Senior Scientist, Dr Jack Prenderville, standing with Minister Mary Mitchell O’Connor T.D –
See also a picture of our General Manager and Scientific Director, Dr Max Bianchi, warmly greeting the Minister –
July 2016 BAP Undergraduate Awards 2016.
This year the BAP Undergraduate Award 2016 was awarded to David O’Driscoll, Research Intern from Transpharmation Ireland Ltd. team, for his poster: ‘An investigation of human plasma protein biomarkers in Burning Mouth Syndrome.’ A Neuropathic syndrome associated to depression.
The awards provide undergraduates with the experience of attending a national scientific meeting and encourages young psychopharmacologists to pursue a research-active career.
See below a picture of David standing next to his award winning poster –
Well done David!
July 2016 Transpharmation Ireland Ltd will attend the BAP Summer Meeting held in Brighton (17th-20th July).
British Association for Psychopharmacology (BAP) promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. This year Transpharmation Ireland Ltd Team will present three posters focused on our new and exciting results on potential biomarkers of Depressive Disorders obtained with our innovative assays.
- “Plasma acetylated α-tubulin expression as an indicator of antidepressant effectiveness.” Presented by Mr. Conor McDonnell (Junior Scientist).
- “The Wistar-Kyoto model of depression shows impaired ultrasonic vocalization response in the Female Urine Sniffing Test when compared with Sprague-Dawley.” Presented by Ms. Grazia Di Capua (Research Assistant).
- “An investigation of human plasma protein biomarkers in Burning Mouth Syndrome.” A Neuropathic syndrome associated to depression, presented by Mr. David O’Driscoll (Research Intern).
For more information about BAP, please follow the link attached to the logo below –
July 2016 Transpharmation Ireland Ltd will present at the 30th CINP World Congress of Neuropsychopharmacology (Seoul, South Korea).
Transpharmation continues to develop its scientific capabilities to support Treatment Resistant Depression Drug Discovery. This year, Transpharmation Ireland Ltd will participate at the CINP with Dr. Jack Prenderville presenting the following poster:
“Single administration of ketamine and Pregnenolone-Methyl- Ether has antidepressant efficacy in a preclinical model of treatment resistant depression: identification of a plasma biomarker of pharmacological efficacy.”
May 2016 Transpharmation Ireland Ltd, a leading Preclinical CRO, attends the Irish Laboratory Awards 2016 as finalists.
The Irish Laboratory Awards (ILA) recognise the successes and achievements of Ireland’s internationally renowned research laboratories and scientists. This year, Transpharmation Ireland Ltd was shortlisted in two categories:
- Start-up Laboratory of the Year.
- Laboratory Team of the Year.
January 2016 Further development of pharmacologically validated behavioural endpoints in rodent pain models.
We are continually adding to our suite of capabilities in the preclinical and clinical pain testing space. As such, we have pharmacologically validated the chemotherapy-induced neuropathy (CIN) and CCI models in the mouse using pregabalin and/or duloxetine. Further to this we have added several sensory modalities/endpoints to these models, including cold and tactile allodynia. Further information can be found at idtech-vitrolles.dyndns.org/bioseb/anglais/default/news.php
If you are interested in discussing these capabilities further to support your drug discovery efforts please contact us.
October 2015 Transpharmation develops best in class treatment resistant depression models.
Recent data suggesting that ketamine may work in patients resistant to treatment with ‘classical’ antidepressants has reignited drug discovery into mood disorders. Even before this reported data, given Transpharmation’s staff historical involvement in the discovery of the SSRI paroxetine, we have been attempting to find various preclinical models of treatment resistant depression (TRD).
Please also see here Max Bianchi talking about these research efforts in our Dublin, Ireland research facility :-
Watch “Transforming Drug Discovery in Depression to Scare Away the Dark”
If you are interested in discussing these capabilities further to support your drug discovery efforts please contact us.
March 2014 Transpharmation launches an Irish subsidiary – called Transpharmation Ireland – based at the Institute of Neuroscience in Dublin, Ireland.
Transpharmation, a translational biology Contract Research Organisation, have recently announced the incorporation of Transpharmation Ireland which will be based at Trinity College in Dublin, Ireland.
The new subsidiary will see the addition of a suite of complementary services to those already offered in the UK; notably with the addition of a clinical Experimental Medicine platform (e.g. Pharmaco-EEG, MRI) together with extended preclinical capabilities.
In addition to the new clinical capabilities, the new subsidiary will focus on the neurobiology of ageing and mood disorders, particularly by combining complex molecular and behavioural endpoints with real time electrophysiological measurements in animals.
Reporting through to the UK parent business, Transpharmation Ireland will be headed by Dr. Massimiliano (Max) Bianchi.
You can see a brief video overview of the Irish business, introduced by Max
We are constantly looking for novel preclinical/clinical assays, technologies and endpoints that increase your success. Wherever possible we strive to publish our research in peer reviewed journals.
A CRO should offer technologies you do not have in your own company. Investment in technology, bringing capabilities together, underpins our desire to innovate & produce multiple endpoints to a single study.